Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

HydraFacial

Also known as: hydra facial, hydrafacial, hydradermabrasion

HydraFacial is a brand of powered hydradermabrasion device made by Hydrafacial LLC, part of SkinHealth Systems Inc. A motorised handpiece pulls a vacuum through a disposable spiral tip while pumping solution onto the skin, combining wet exfoliation, suction extraction and topical delivery in one pass.

Evidence status

Manufacturer-supported

Small studies are compatible with short-term exfoliation, hydration, comedone reduction and appearance improvement; an independent eight-person imaging study found temporary stratum-corneum change. No randomised trial compares a HydraFacial-branded device with sham, a manual facial or another device, and no evidence supports collagen remodelling. The branded acne study was open-label with a company employee among the authors, while other studies test bundled serums or competing devices, so the HydraFacial handpiece's independent effect remains uncertain.

What HydraFacial is, and the types available#

HydraFacial is a brand of powered hydradermabrasion made by Hydrafacial LLC, part of SkinHealth Systems Inc. A motorised handpiece draws vacuum through a single-use spiral tip while delivering liquid, combining abrasion, suction and topical application in one pass. FDA lists the generic device type as “Brush, Dermabrasion, Powered”.[1, 6]

The manufacturer's IFU gives a narrow intended use: exfoliation of the upper layers of skin. In the EEA, the medical Syndeo build carries indications for mild-to-moderate acne vulgaris and comedonal acne, and superficial acne scarring. It is Class IIa under EU MDR 2017/745 and carries no EEA rejuvenation, anti-ageing or pigmentation indication.[6][6]

HydraFacial publishes separate medical-device and non-medical Syndeo manuals. The non-medical build omits the acne indication, EU MDR classification, GMDN/EMDN codes and notified-body number while retaining the same intended use, contraindications and UKCA/CE symbols. Machines that look alike may therefore have different regulatory identities.[6, 7]

Syndeo, Elite and Allegro names describe the brand's equipment family. The entry does not treat generic “hydrafacial-style” machines or Allergan's DiamondGlow as equivalent: no independent comparative study establishes equivalence.

Use of HydraFacial in aesthetic practice#

In Great Britain, device status follows the UK Medical Devices Regulations 2002, MHRA registration, the applicable conformity mark and the manufacturer's UK intended purpose. Syndeo labelling carries UKCA and CE symbols and names Responsible Person Ltd in Edinburgh as the UK Responsible Person. Northern Ireland follows the EU device framework.[6]

No national practitioner licence or minimum qualification specific to HydraFacial is established here for Great Britain. Manufacturer training, local-authority requirements, insurance and the exact device IFU are the operative gates. Hydradermabrasion is outside the JCCP's five modality groups, Wales' four special procedures and, on the face of Scotland's 2026 Act, procedures defined by skin penetration. The practitioner-licensing position in Northern Ireland must be checked separately from its EU device-market route.

US FDA status must be described accurately. HydraFacial delivery systems are listed under product code GFE as Class-I devices exempt from 510(k) premarket notification. They have not been FDA-cleared. The company's historical 510(k)s concern two LED systems and sterile tubing, not HydraFacial delivery systems.[16] A US classification would have no UK legal standing in any event.[1, 4]

The operating company is Hydrafacial LLC, formerly Edge Systems LLC. Its parent, SkinHealth Systems Inc (Nasdaq: SKIN), was named The Beauty Health Company until April 2026. The UK arm is HYDRAFACIAL UK LIMITED, incorporated in 2019.[9][4, 5]

No UK-specific clinical guidance on hydradermabrasion — from NICE, the British Association of Dermatologists, the JCCP or any Royal College — and no MHRA device safety alert naming HydraFacial could be located.[no source found]

Contraindications and cautions#

The manufacturer lists active or inflammatory acne, eczema or dermatitis, rashes, psoriasis, sunburnt or injured skin, active herpes simplex, open lesions, skin infection and fragile skin as contraindications. Pregnancy and lactation, isotretinoin within the previous six months, and use over the orbital area or a body orifice are also listed.[6]

This creates an important labelling tension: the EEA medical build is indicated for mild-to-moderate acne vulgaris and comedonal acne while the same IFU contraindicates active or inflammatory acne.[6] The conservative reading is that non-inflamed comedonal disease differs from actively inflamed lesions; the device's current local labelling and clinical assessment govern.

Thin or sensitive skin, including rosacea, is addressed in the IFU through adjusted vacuum, handpiece pressure and solution selection.[6] Those product-specific instructions should be followed rather than replaced by a generic Skinipedia setting. Active cold sores are contraindicated; a history of recurrence requires the relevant medical pathway.

Because the procedure combines suction, abrasion, acids, topicals and sometimes LED, suitability for one component does not establish suitability for all. Uncertain lesions, impaired healing, acute infection and ocular vulnerability require deferral or referral.

Clinical uses and the evidence behind them#

Exfoliation and surface change

This is the manufacturer's stated intended use and the clearest independent finding. In eight volunteers, imaging found stratum-corneum thickness fell from 9.42 to 6.67 μm immediately after treatment and measured 9.75 μm at two weeks, with more homogeneous corneocytes and fewer epidermal undulations. No visible change in dermal collagen quality or quantity was found at two weeks.[12]

Acne and comedones

The only HydraFacial-branded clinical study was a two-site, open-label series of 20 people with mild-to-moderate acne. After six treatments, investigator-rated clear or almost-clear skin increased from 20% to 65% (p=0.0027), and self-rated clear or almost clear from 5% to 55% (p=0.0016). The authors concluded that acne severity improved. There was no control, randomisation or blinding; the endpoint was a global severity score, and one author was a manufacturer employee.[11]

One generic controlled study provides a narrower signal for suction. In a split-face comparison of 23 women, one side received 4% AHA and the other the same acid with negative pressure. Whiteheads and blackheads fell from baseline through four weeks only on the negative-pressure side, and that side was significantly better at week one; the between-side advantage did not persist at weeks two and four. No HydraFacial device was named.[15]

Topical delivery and hydration

Freedman 2008 randomised 20 women between six hydradermabrasion treatments with polyphenolic serum and six manual applications of the same serum. Biopsies found increased epidermal and papillary-dermal thickness and higher antioxidant levels only in the device group (p<0.01). The abstract does not state arm sizes or name the device, and no funding or conflict statement was published; it cannot be assumed to be HydraFacial evidence.[10]

The wider hydradermabrasion literature

The most recent and largest paper indexed under hydradermabrasion tested Allergan's competing DiamondGlow device with Allergan serums in a 29-person open-label uncontrolled study funded and staffed by Allergan. It is evidence about that system, not HydraFacial.[13]

Across the indexed literature, no randomised HydraFacial comparison with sham, a manual facial or another device, and no systematic review, is available. The single controlled comparison concerns a generic acid-plus-negative-pressure mechanism.[10, 11, 12, 13, 15]

Selecting a HydraFacial system#

Selection starts with the exact build: medical or non-medical, intended use, conformity documentation, installed handpiece and available consumables.[6, 7] A clinic's model name alone does not establish its EEA indication or regulatory configuration.

Each treatment component adds a separate decision. Exfoliation, acid solution, suction, extraction, topical boosters, lymphatic massage and LED do not share one evidence base. The manufacturer's UK consumer site now describes seven personalised elements, whereas the familiar “three-step Vortex-Fusion” phrase does not appear in the current Syndeo IFU.[6, 8]

No study dismantles the full branded sequence sufficiently to assign the outcome to abrasion, suction, serum, LED or massage. The current IFU and manufacturer training therefore govern tip, solution, vacuum, sequencing and any product-specific treatment schedule. Generic copies cannot be assumed equivalent from appearance alone.

Adverse effects and their management#

Expected transient responses

Temporary erythema, tightness, sensitivity or a short-lived breakout can follow combined abrasion, suction and active-solution exposure. Persistent or worsening inflammation is not an efficacy marker and should be reassessed.

Ocular exposure

One 2013 MAUDE filing described acid solution entering a client's eyes when protection was not used, with reported tear-duct stenosis, mild periorbital cellulitis and bilateral lower-eyelid punctoplasty. The event reached the manufacturer through litigation years later and does not establish incidence; it shows the potential consequence of fluid or acid exposure near the eye.[3]

Erythema and dyspigmentation

The second of only two HydraFacial MAUDE reports described persistent facial erythema and a full-face breakout in a person with darker skin.[3] Two passive reports over more than a decade cannot define risk or reassure about its absence.

Infection control and fluid pathways

The IFU states that tips are single-use and warns that re-use can cause infection. Solutions that are opened or contaminated must not be re-used. It requires a 60-second system rinse after extraction and after each treatment, mechanical brushing of both handpiece chambers, and two germicidal wipes leaving the handpiece wet for two minutes; it states that isopropyl alcohol is not a suitable disinfectant.[6][6]

Manufacturer maintenance schedules call for manifold cleaning every 50 treatments or weekly, whichever comes first; emptying the waste canister after every treatment and daily washing; and tubing replacement every six months. These are named-manufacturer instructions, not a generic hydradermabrasion protocol.[6]

The company has acknowledged serum build-up, low flow and clogging in Syndeo 1.0 and 2.0 and said Syndeo 3.0 was designed to force rinse cycles and manifold cleaning. No real-world microbiological or biofilm sampling of hydradermabrasion fluid paths is available, so adequacy against waterborne organisms rests on design and adherence rather than measured field outcomes.[4][no source found]

Referral and scope boundaries#

Spreading erythema, increasing pain, fever, purulent discharge, ocular exposure with ongoing symptoms, visual change, marked swelling, blistering or suspected infection requires medical assessment. Device malfunction or a serious incident also follows the manufacturer's vigilance route and the MHRA reporting pathway where applicable.

Active inflammatory acne, eczema, psoriasis, herpes, injured skin and recent isotretinoin use are manufacturer-listed exclusions, not opportunities to modify a generic setting.[6] Medical acne requiring diagnosis or prescription care follows the acne pathway.

No nontuberculous-mycobacterial outbreak has been linked to HydraFacial in the published or FDA record. The 2022–2023 US cluster sometimes conflated with the brand involved 15 Mycobacterium abscessus infections after liposuction, mostly with gluteal fat transfer, at one Florida surgery clinic; no facial device was implicated.[2, 3][14]

Mechanism of action#

The spiral tip and vacuum provide mechanical surface abrasion and negative pressure while liquid is delivered to the interface. This removes part of the stratum corneum, mobilises superficial follicular material and leaves water and topical ingredients on the surface.[1, 6, 12]

The 2015 split-face study suggests negative pressure added an early comedone effect beyond acid alone, although the between-side difference was short-lived and no commercial device was named.[15] No independent imaging evidence shows dermal collagen remodelling at two weeks.[12]

Commonly misstated claims#

“HydraFacial is FDA approved or FDA cleared.”

HydraFacial delivery systems are Class-I 510(k)-exempt devices in the US. Registration and listing do not amount to clearance or approval.[1, 4, 16]

Supported statement: HydraFacial is listed in the US as a Class-I exempt powered dermabrasion device; UK status follows separate UK regulation.

“A 2023 mycobacterial outbreak caused a HydraFacial recall.”

No FDA recall or HydraFacial-linked NTM outbreak appears in the regulatory or published record.[3] The actual outbreak involved surgery at a Florida clinic, while the 2023 Syndeo programme addressed low flow and clogging.[14][2, 4]

Supported statement: no HydraFacial NTM outbreak or recall was found; Syndeo received a commercial hardware enhancement programme for fluidics issues.

“HydraFacial builds collagen.”

The only independent imaging study found no visible dermal-collagen change at two weeks. The often-cited histology study did not name the device and combined hydradermabrasion with antioxidant serum.[10, 12]

Supported statement: short-term exfoliation and epidermal change are measured; brand-specific collagen remodelling is not established.

“It is a fixed three-step treatment.”

The current IFU does not use the legacy three-step phrase, while current UK marketing lists seven elements.[6, 8]

Supported statement: HydraFacial is a configurable branded sequence whose components and indications depend on the installed system and selected consumables.

The consumer claim that the lymphatic step 'supports skin detoxification' has no clinical referent in the manufacturer's own regulatory documents, where the sole intended use is exfoliation of the upper layers of the skin.[8, 6]

Areas of remaining uncertainty#

  • Which component produces each outcome; without dismantling studies, abrasion, suction, serum, LED and massage cannot be credited separately.
  • Whether the 2008 histology study used HydraFacial; without a named device, it cannot support a brand-specific claim.[10]
  • Whether a maintained Syndeo fluid path stays free of biofilm under real clinic throughput; without sampling, infection-control effectiveness cannot be quantified.
  • How long appearance benefits persist; follow-up is short and the independent stratum-corneum change had reversed by two weeks.[12]
  • Whether adverse-event risk differs by phototype; existing studies are too small to detect a meaningful pigment signal.

Frequently asked questions#

Is HydraFacial FDA cleared?

No. The delivery system is Class-I and exempt from 510(k) premarket notification in the US.[1, 16, 4]

Does it build collagen?

Independent imaging found no visible dermal-collagen change at two weeks.[12]

Is it suitable for active acne?

The EEA build has an acne indication, but the IFU contraindicates active or inflammatory acne. The current local device labelling and clinical assessment govern; inflamed disease should not be treated as simple comedonal congestion.[6]

Can a generic hydradermabrasion machine be treated as equivalent?

No comparative evidence establishes equivalence in delivery, consumables, infection control, regulatory status or outcome.

What cleaning schedule applies?

The exact manufacturer's IFU applies. Syndeo's published requirements include single-use tips, post-treatment rinsing and brushing, specified disinfectant contact and scheduled manifold and tubing maintenance.[6]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. US Food and Drug Administration, Device Registration and Listing Database and Product Classification Database, records for HydraFacial LLC and product code GFE (queried via the openFDA API).Tier 1Supports: Registrant HydraFacial LLC, 3600 E. Burnett St., Long Beach, CA 90815; establishment type 'Manufacture Medical Device'; listing created 2001-08-07. Proprietary names on the listing include HydraFacial Syndeo, HydraFacial MD Elite, HydraFacial MD Allegro, HydroPeel Tip variants and Keravive Tip. All are listed under a single product code, GFE, device name 'Brush, Dermabrasion, Powered', regulation number 878.4820, device_class 1. The GFE classification record returns device_class 1, medical_specialty_description 'General, Plastic Surgery', gmp_exempt_flag 'N', implant_flag 'N'. A separate 510(k) query for applicant 'Edge Systems' (HydraFacial LLC's former name) returns only three clearances, none of them a HydraFacial device: K061470 Del Sol Blue Light Therapy System (2006), K072399 Del Sol Red Light Therapy System (2008) and K990748 Edge Systems Sterile Tubing (1999). SCOPE LIMIT: registration and listing are administrative acts, not FDA review, clearance or approval of the device; a listing record says only that the firm told FDA it makes the product.
  2. US Food and Drug Administration, Medical Device Recalls database (accessdata cfRES) and openFDA device/enforcement and device/recall endpoints, searched for 'HydraFacial', 'Syndeo' and recalling firms HydraFacial / Edge Systems / BeautyHealth.Tier 1Supports: The FDA Medical Device Recalls database returns, verbatim, 'No records were found with Product : hydrafacial'. The openFDA device/enforcement and device/recall endpoints return HTTP 404 NOT_FOUND (zero matching records) for recalling_firm 'HydraFacial'. The only record in the FDA recall database containing 'Syndeo' is an unrelated device: Baxter Healthcare Corporation's Syndeo PCA Syringe Pump (models 2L3113/2L3113R), recall number Z-1373-05, event initiated 2005-07-06, 4,392 units, root cause 'Device Design', terminated 2011-06-27. SCOPE LIMIT: these databases cover recalls and corrections reported to FDA under 21 CFR Part 806/7. A commercial upgrade programme, service action or market withdrawal that a firm did not report as a correction or removal would not appear here.
  3. US Food and Drug Administration, MAUDE (Manufacturer and User Facility Device Experience) database, queried via openFDA device/event for device.brand_name 'HydraFacial' and manufacturer names 'Edge Systems' / 'HydraFacial'.Tier 1Supports: Two reports in total, both coded 'Injury'. (1) Report number 2031227-2013-00001, received 2013-05-06, generic name 'GFE, HYDRADERMABRASION': the manufacturer narrative states 'THE INCIDENT OCCURRED IN 2010, BUT WAS NOT BROUGHT TO EDGE SYSTEMS' (MANUFACTURER) ATTENTION UNTIL RECENTLY BY THE LAWSUIT BETWEEN THE CONSUMER AND THE HEALTH PROFESSIONAL' — so the event dates from 2010 and reached FDA only via litigation three years later. The suspect glycolic/salicylic acid cosmetic products were 'USED IN CONJUNCTION WITH THE HYDRAFACIAL WAVE DEVICE'; the operator 'FAILED TO FOLLOW INSTRUCTIONS FOR USE AND PRECAUTION TO PROPERLY COVER AND PROTECT PATIENT'S EYES DURING FACIAL TREATMENT, CAUSING THE ACIDIC FLUIDS TO GET INTO PATIENT'S EYES'. Reported injuries, verbatim: 'EXCESSIVE TEARING OF BOTH EYES; ITCHINESS, SWELLING, AND BURNING SENSATION OF THE EYES AND SURROUNDING AREAS; RASH AN IRRITATED SKIN; MILD CONTACT DERMATITIS; LACRIMAL TEAR DUCT STENOSIS; MILD SINUSITIS WITH NASAL OBSTRUCTION; MILD PERIORBITAL CELLULITIS'; also blurry vision and light sensitivity. The patient 'UNDERWENT A BILATERAL LOWER EYELID PUNCTOPLASTY' and 'WAS CONFINED TO HER HOME FOR APPROXIMATELY 30 DAYS INTERMITTENTLY'. Manufacturer analysis attributed it to operator error and reported that the suspect lots showed 'NO MICROBIAL GROWTH OR DEFECTS'. (2) Report number MW5095261, received 2020-06-26, brand name HYDRAFACIAL, manufacturer 'HYDRAFACIAL/EDGE SYSTEMS LLC' — but coded under the generic name 'POWERED LASER SURGICAL INSTRUMENT', which is a miscoding for this device. Consumer report, verbatim: 'I HAD A HYDRAFACIAL PROCEDURE DONE AND THE NEXT DAY MY FACE APPEARED REDDISH IN COLOR WITH A BREAKOUT ON MY ENTIRE FACE. I AM AFRICAN AMERICAN WITH DARK COLORED SKIN AND THE REDDISH COLOR APPEARS TO BE PERMANENT DAMAGE TO MY SKIN.' No report in the database concerns mycobacterial or any other device-transmitted infection. SCOPE LIMIT: MAUDE is a passive, voluntary system for lay and user reports; a Class I 510(k)-exempt device used in non-healthcare settings generates almost no reporting, so two reports is evidence about the reporting system, not about incidence.
  4. The Beauty Health Company (now SkinHealth Systems Inc.), Annual Report on Form 10-K for the fiscal year ended 31 December 2025, filed with the US Securities and Exchange Commission 12 March 2026 (CIK 0001818093). EDGAR records the registrant as 'Beauty Health Co' for filings through 20 April 2026; the SkinHealth Systems name took effect 22 April 2026, after this filing.Tier 4Supports: Regulatory status, verbatim: 'Each Delivery System is considered to be a Class I exempt medical device pursuant to the rules and regulations promulgated by the U.S. Food and Drug Administration'. Consumables, verbatim: 'Consumables consist of single-use tips, solutions, and serums used to provide a Hydrafacial treatment'. Device performance history, verbatim: customers with Syndeo 1.0 and 2.0 builds 'began to experience frequent treatment interruptions', including 'low flow and clogs in the system, due to recommended maintenance requiring overly rigorous levels to prevent serum build-up inside the system's fluidics manifold'; in July 2023 the Company developed Syndeo 3.0 with 'hardware and software enhancements that automate and force effective rinse cycles and manifold cleaning with an air blast procedure that reduce build-up and clogging as well as improvements in the connector to the handpiece to facilitate user cleaning'; in Q3 2023 it announced the 'Syndeo Enhancement Program' to upgrade devices to 3.0 standards by field service, and in October 2023 decided to market and sell only Syndeo 3.0, offering customers a free field upgrade or a replacement device plus a one-year warranty extension. Corporate lineage: the registrant was incorporated in Delaware on 8 July 2020 as Vesper Healthcare Acquisition Corp; on 4 May 2021 it completed a business combination with LCP Edge Intermediate, Inc., 'the indirect parent of HydraFacial LLC, (f.k.a. Edge Systems LLC)'. UK framework, as described by the filing: since 1 January 2021 the MHRA is the regulator for Great Britain under the UK Medical Devices Regulations 2002 (SI 2002 No 618, as amended); devices must be registered with the MHRA; non-UK manufacturers must appoint a UK Responsible Person with a registered place of business in the UK; 'All medical devices require in principle a UK Conformity Assessed (UKCA) mark, but manufacturers can continue to place CE marked medical devices on the UK market during a transitional period'; Northern Ireland continues under EU rules. The filing's only references to recall are generic risk-factor and enforcement-power boilerplate; it discloses no product recall of any HydraFacial device, and contains no reference to mycobacteria or infection outbreaks.Funding / interest: This is the manufacturer's own SEC annual report. SkinHealth Systems Inc. (Nasdaq: SKIN) is the commercial owner of the HydraFacial brand and has a direct financial interest in the characterisation of its devices and of the 2023 Syndeo actions. It is used here for statements against interest (device defects, regulatory class) and for corporate facts, not for efficacy.
  5. SkinHealth Systems Inc., Current Report on Form 8-K, date of earliest event reported 17 April 2026, filed 22 April 2026 (Items 5.02, 5.03, 7.01, 9.01).Tier 4Supports: Item 5.03, verbatim in substance: on 21 April 2026 the Company filed a third certificate of amendment with the Delaware Secretary of State 'to change the Company's name to SkinHealth Systems Inc.'; the amendment 'became effective at 12:01 a.m. E.T. on April 22, 2026'. The cover page names the former registrant as 'The Beauty Health Company', principal executive offices 3600 E. Burnett Street, Long Beach, CA 90815, Class A Common Stock trading as SKIN on the Nasdaq Capital Market. A corporate rebrand press release was filed as Exhibit 99.1. SCOPE LIMIT: this is a corporate name change at parent level; the operating entity remains Hydrafacial LLC and the brand name on the device is unchanged.Funding / interest: Filing by the manufacturer's parent company; used only for corporate identity facts.
  6. Hydrafacial LLC. Hydrafacial Syndeo Instructions for Use (medical device version), P/N 1900104-G, revision printed as 'Rev. 03/04/2026', English, 29 pages.Tier 4Supports: Operator scope, verbatim: 'The System is intended to be used in clinics, hospitals, doctor's offices, and aesthetic practices by trained and licensed practitioners, such as dermatologists, facial plastic surgeons, physicians, and aesthetic professionals - in accordance with their licensing scope and applicable national/local requirements.' Intended use, verbatim: 'The System is intended to exfoliate the upper layers of the skin.' EEA indication, verbatim: 'Mild to moderate acne, i.e. acne vulgaris, comedonal acne (blackheads and whiteheads)' and 'Superficial acne scarring'. Classification, verbatim: 'The above have been assessed and supported by clinical evaluation in accordance to the Medical Device Regulation (EU) 2017/745 Annex VIII... The Hydrafacial Syndeo is a Class IIa medical device in the EEA; GMDN Code 11177, EMDN Code Z12040299.' UK representation, verbatim: 'Responsible Person in the United Kingdom: Responsible Person Ltd. Summit House, 4-5 Mitchell Street, Edinburgh, EH6 7BD, UK'; EC Rep Ltd, Dublin; a Swiss authorised representative; and the number 1639 printed alongside (this number appears in the medical-device IFU only, not in the non-medical version). The symbols key prints the CE symbol name in accented French, as 'Conformite Europeenne' with acute accents. The symbols key lists both 'UK Conformity Assessment' and 'Conformite Europeenne', plus 'Do Not Re-use'. Tips, verbatim: 'Disposable tips suspected of being damaged should be discarded and replaced... Single use only', and in the safety guidelines 'Always use clean, unused tips for each treatment. Keep tips in original packaging until ready to use. Reusing tips could result in skin infection.' Also 'Use only tips manufactured by Hydrafacial LLC' and 'Do not use contaminated skin solutions. Reusing contaminated skin solution could result in skin infection, and will void all warranties.' Handpiece cleaning, verbatim: 'Insert the Cleaning Brush into the vacuum (smaller) opening on the face of the handpiece. Push the brush in and out fully while rotating three times. Repeat on the blue twist lock connector opening on the back of the handpiece.' Then 'Wash the brush bristles in soapy water between each handpiece opening insertion to clean off debris.' Then then 'Clean the entire outer surface of the handpiece with a germicidal wipe, removing all visible soil. Use a second germicidal wipe to thoroughly wet the surface of the handpiece and ensure the handpiece remains visibly wet for 2 minutes.' Note, verbatim: 'Barbicide is a recommended disinfectant (follow Barbicide's instructions for use). Isopropyl alcohol is not suitable as a disinfectant.' And: 'It is recommended to replace handpiece tubing every six months and the handpiece as needed.' Manifold cleaning: 'Perform after every 50 treatments or every week (whichever comes first)', using Rinseaway Complete through each of four slots. Routine maintenance lists three separate 60-Second System Rinses: an 'In-Treatment 60-Second Rinse' 'after the Extraction step of each treatment', an 'After Each Treatment 60-Second Rinse', and an 'End of Day 60-Second Rinse'; empty the #Gunkie waste canister after each treatment and rinse with water, rinse with soap and water at end of day and air dry; do not let it fill above 450 mL. Contraindications, verbatim list: infants, children, pregnant or lactating women; 'Individuals with any active skin conditions on the treatment area, including but not limited to: active or inflammatory acne, eczema or dermatitis, rashes, psoriasis, sunburnt or injured skin, active cold sores or Herpes Simplex Virus, open lesions, skin infections, and fragile skin'; 'Over abnormal, unidentified facial growth, marks or lesions suspected of melanoma or other malignancies'; 'Individuals taking Accutane or Isotretinoin medications 6 months prior to treatment'; known ingredient allergy; over the orbital area or any body orifice. Warnings include seeking physician guidance for autoimmune disease, cancer, vascular disorders and communicable diseases, and for skin-thinning medication (immunosuppressants, chemotherapy, long-term tetracyclines, anticoagulants, prolonged corticosteroids); a warning for individuals who have had surgical, invasive or ablative aesthetic treatment to the treatment area; and, verbatim, 'Individuals with predisposition to cold sores or Herpes Simplex Virus may be managed through the implementation of a prophylactic regimen'; and 'Lower vacuum settings, lighter handpiece pressure, and appropriate skin solution selection may be used in individuals with thin skin or sensitive skin conditions (e.g. rosacea).' Side effects, verbatim: 'Client may experience temporary irritation, tightness, or redness at the treatment area. This usually dissipates within 72 hours depending on skin sensitivity.' The document contains no occurrence of the words 'Vortex', 'Fusion' or 'Hydrate' as a named treatment step. VERIFIED 2026-08-02: the PDF was downloaded and text-extracted independently; every quotation above matches the document. The strings 'Vortex', 'Fusion' and 'Hydrate' return zero occurrences across all 29 pages.Funding / interest: Manufacturer's own device labelling. Hydrafacial LLC has a direct commercial interest; the tip and solution single-use requirements also lock the user into the manufacturer's consumables, which the same document ties to warranty validity.
  7. Hydrafacial LLC. Hydrafacial Syndeo Instructions for Use (non-medical device version), P/N 1900125-D, revision printed as 'Rev. 10/07/2025', English, 29 pages.Tier 4Supports: A separately published manual for non-medical-device Syndeo SKUs, identified in its own specifications table as 7000079-BLK-NMD (220-240V) and 7000078-BLK-NMD (100-120V). It carries the same intended use ('The System is intended to exfoliate the upper layers of the skin'), the same contraindications, warnings, side-effect wording, cleaning and maintenance protocol, the same UK Responsible Person and EC Rep block, and the same 'UK Conformity Assessment' and 'Conformite Europeenne' symbols in the key. It contains NO EEA acne or acne-scarring indication, NO statement of medical device classification under EU MDR 2017/745 or Class IIa, no GMDN or EMDN code, and — verified by text extraction — no occurrence of the notified body number 1639 that appears in the medical-device version. The manufacturer's electronic IFU index lists 'Medical' and 'Non-Medical' variants side by side for the Syndeo, Elite and Del Sol product lines. SCOPE LIMIT: this establishes that two documented build/labelling variants exist; it does not establish which variant predominates in the UK installed base.Funding / interest: Manufacturer's own device labelling.
  8. Hydrafacial LLC. Hydrafacial United Kingdom consumer website, hydrafacial.co.uk, homepage and treatment section.Tier 4Supports: Current UK consumer positioning, verbatim: 'Get The Best Skin Of Your Life'; 'Discover the ultimate solution for achieving glowing, hydrated and healthy skin'; 'Seven personalized skin treatments in one'; 'Explore how the 7 Hydrafacial treatment steps works together to visibly enhance glow and restore a refreshed, radiant complexion.' The seven named steps are: lymphatic, microdermabrasion, peel, extract, target, LED, hydrate. Step claims, verbatim: 'Lymphatic Drainage — Gentle suction supports skin detoxification and helps reduce puffiness, giving you a more sculpted, lifted look' (bullets: 'Supports Skin Detoxification', 'Helps Reduce Puffiness', 'Gives Skin a Firmer Look'); 'Microdermabrasion — Our physical exfoliating step cleanses and gently lifts away dead skin cells, revealing smoother, brighter looking skin' (bullets: 'Deep Cleanse', 'Gently Exfoliates', 'Reveals Smoother Looking Skin'). The phrase 'Vortex-Fusion' and any three-step framing do not appear on the current UK homepage. VERIFICATION NOTE 2026-08-02: an independent re-fetch confirmed the headline 'Get The Best Skin Of Your Life', the claim 'Seven personalized skin treatments in one', the '7 Hydrafacial treatment steps' framing, the seven step names, and the absence of 'Vortex-Fusion' anywhere on the page. The per-step bullet wording quoted above sat below the point at which the re-fetch truncated and was not re-verified in this session. SCOPE LIMIT: this is marketing copy with no cited evidence; 'supports skin detoxification' in particular has no clinical referent.Funding / interest: Manufacturer's own consumer marketing site, published by Hydrafacial LLC.
  9. Companies House (UK), company record for HYDRAFACIAL UK LIMITED, company number 11776522.Tier 1Supports: Status Active; private limited company; incorporated 18 January 2019; registered office 10 Portman Square, London, W1H 6AZ; SIC code 96020 'Hairdressing and other beauty treatment'; last accounts made up to 31 December 2024, next accounts due by 30 September 2026; last confirmation statement dated 17 January 2026, next due 31 January 2027; no previous names recorded. SCOPE LIMIT: the SIC code is self-declared at registration and is a beauty-services code, not a medical device code; it carries no regulatory meaning for the device itself.
  10. Freedman BM. Hydradermabrasion: an innovative modality for nonablative facial rejuvenation. J Cosmet Dermatol. 2008 Dec;7(4):275-80. PMID 19146604.Tier 3Supports: Twenty female volunteers aged 34-56, 'randomized into two groups'. Group A received six facial hydradermabrasion treatments with a polyphenolic antioxidant serum, 7-10 days apart. Group B received the same serum applied manually, six times at the same interval. Digital photographs, skin biopsies and skin polyphenolic antioxidant levels were taken before and after; patient surveys were taken afterwards. Group A showed increased epidermal thickness, papillary dermal thickness and polyphenolic antioxidant levels (P < 0.01), replacement of elastotic dermal tissue, collagen hyalinisation and increased fibroblast density; fine lines, pore size and hyperpigmentation decreased; no complications reported. Group B showed 'no change in skin structure, antioxidant levels, or clinical skin attributes.' SCOPE LIMITS: n=20 total; the abstract does NOT state the size of each arm, so the commonly repeated 'ten per group' is an inference, not a reported figure; single centre; single operator; no blinding of subjects, operator or histopathologist described in the abstract; no sham device arm, so the comparison is device-plus-serum versus serum alone rather than device versus sham; the abstract does not name the device or manufacturer, so it cannot be confirmed from the abstract that a HydraFacial-branded unit was used; the journal published no funding or conflict-of-interest statement with this 2008 article and full text could not be accessed (Wiley returned HTTP 402; Europe PMC records the article as closed access with no grants list).Funding / interest: No funding or conflict-of-interest statement was published with this article. The author was in private plastic surgery practice (Plastic Surgery Associates of Northern Virginia). Absence of a declaration in a 2008 cosmetic-dermatology paper should not be read as absence of a commercial relationship.
  11. Storgard R, Mauricio-Lee J, Mauricio T, Zaiac M, Karnik J. Efficacy and Tolerability of HydraFacial Clarifying Treatment Series in the Treatment of Active Acne Vulgaris. J Clin Aesthet Dermatol. 2022 Dec;15(12):42-46. PMID 36569524, PMCID PMC9762628.Tier 3Supports: Twelve-week, multicentre, open-label study. Twenty adult patients with mild-to-moderate acne enrolled at two US sites (MBeauty Clinic, San Diego, California and Mount Sinai Medical Center, Miami Beach, Florida), each to receive six HydraFacial Clarifying Treatments, one every two weeks for 12 weeks. The treatment is described in three steps: cleansing and peeling; suction to extract dead skin cells, sebum and debris; application of blue LED light. Primary outcome Global Acne Severity Score (GASS). Patients with GASS <=1 ('no acne or almost clear') rose from 20% to 65% by investigator assessment (p=0.0027) and from 5% to 55% by patient self-report (p=0.0016), baseline versus final treatment. More than 80-100% of investigators and patients agreed or strongly agreed there was improvement across multiple parameters. Treatments 'generally well tolerated'. The authors' own conclusion, verbatim: 'This first clinical study of HydraFacial Clarifying Treatment demonstrated the therapy was well tolerated and resulted in a significant improvement in acne severity per both investigator and patient assessment following six treatments over 12 weeks.' Stated limitations, verbatim in substance: 'Due to the nature of the treatment, blinding of neither investigators nor patients was feasible'; the study was nonrandomised, small (n=20) and lacked an appropriate placebo control. SCOPE LIMITS: n=20, no control or comparator arm, no randomisation, no blinding, no long-term follow-up; the endpoint is a global severity score, not inflammatory or non-inflammatory lesion counts.Funding / interest: The paper states 'No funding was provided for this article.' One author, Jwala Karnik, is listed by affiliation as 'The HydraFacial Company in Long Beach, California' — the device manufacturer. The published conflict-of-interest statement reads: 'DISCLOSURES: Dr. Kwala is an employee of The Hydrafacial Company. The other authors report no conflicts of interest relevant to the content of this article.' 'Kwala' is evidently a typographical corruption of the author's forename, Jwala (Karnik); the manufacturer employment is disclosed and is corroborated by the affiliation list. NOTED DISCLOSURE GAP: one of the two study sites, MBeauty Clinic, is a private aesthetic clinic and two authors (Tess Mauricio, Jana Mauricio-Lee) share its principal's surname; the paper declares no conflict for either. Site-ownership or practice interests of investigators are not stated either way in the published disclosure.
  12. Razi S, Truong TM, Khan S, Sanabria B, Rao B. Hydradermabrasion through the lens of Line-Field Confocal Optical Coherence Tomography. Skin Res Technol. 2024 Apr;30(4):e13684. PMID 38558475, PMCID PMC10983707.Tier 3Supports: Eight volunteers, Fitzpatrick skin types II-V. Line-Field Confocal Optical Coherence Tomography (LC-OCT; DeepLive, DAMAE Medical) images taken before treatment, immediately after, and at two weeks. Average stratum corneum thickness fell from 9.42 micrometres to 6.67 micrometres immediately after hydradermabrasion; at two-week follow-up it was 9.75 micrometres, 'resulting in an overall increase in the average thickness after treatment'. Improved homogenisation of the stratum corneum and fewer epidermal undulations were seen post-treatment. In all subjects the superficial dermis 'appeared stretched, which returned to baseline by the 2-week follow-up'. Key negative, verbatim: 'At the 2-week follow-up, there were no visible differences in the quality and quantity of collagen fibers in the dermis.' The paper opens by stating that 'Hydradermabrasion, also known as HydraFacial, is an exfoliative cosmetic procedure... Despite its increasing popularity, clinical studies validating its efficacy with non-invasive assessment of histological changes to the skin, are scarce.' SCOPE LIMITS: n=8; single treatment; no control or untreated comparison site described; the device is described only as 'A commercially available hydradermabrasion device' and is not named; outcomes are imaging measurements, not clinical endpoints; two-week follow-up only.Funding / interest: Published conflict-of-interest statement, verbatim: 'The authors declare no conflict of interest.' Authors are affiliated with Rao Dermatology (private practice) and Rutgers Robert Wood Johnson Medical School. This is the only clearly independent study in the set.
  13. Huang P, Mehta R, Emmerich T, Jiang LI, Makino E. Efficacy and tolerability of a novel cosmetic growth factor serum when used as part of biweekly diamond tip hydradermabrasion treatments on facial skin. J Cosmet Dermatol. 2024 Apr;23(4):1304-1312. PMID 38357748.Tier 3Supports: Twenty-nine women aged 25-65 with mild to severe facial photodamage (Fitzpatrick II-VI; 52% White, 41% African American) received six biweekly in-office DiamondGlow hydradermabrasion treatments with TNS Advanced+ Pro-Infusion Serum, plus at-home twice-daily TNS Advanced+ Serum, over 12 weeks. Immediate significant improvements after one treatment for fine lines/wrinkles, visual and tactile skin smoothness, radiance and hydration (all p <= 0.004). From weeks 6-12 all investigator-assessed parameters improved versus baseline (all p <= 0.002 at week 12). Mean tolerability scores were <1 across parameters. 100% of subjects were satisfied with results at weeks 2-12. SCOPE LIMITS: this is NOT a HydraFacial device — DiamondGlow is Allergan Aesthetics' competing hydradermabrasion system. Prospective but open-label, single-arm, no control, no sham, no randomisation; the intervention bundles device, in-office serum and a 12-week at-home regimen, so no component effect can be isolated. A related paper sharing two authors (Goberdhan L, Schneider K, Makino ET, Bautista A, Mehta RC. 'Efficacy and safety of novel topical pigment-correcting regimen with biweekly diamond tip microdermabrasion procedures on facial hyperpigmentation.' J Cosmet Dermatol 2024;23(5):1726-1733, PMID 38288515) reported comparable results in 18 subjects (Fitzpatrick I-IV) in a 12-week open-label uncontrolled design, with 94.1% subject satisfaction. NOTE: that paper describes itself as diamond tip MICROdermabrasion, not hydradermabrasion, and is not returned by a PubMed search for 'hydrafacial OR hydradermabrasion'; it is cited here as context only.Funding / interest: The paper is funded by Allergan Aesthetics, an AbbVie Company — which manufactures and markets both the DiamondGlow device and the TNS serums under test. The byline comprises Allergan Aesthetics personnel (Huang, Mehta, Makino, Irvine, California) and staff of SGS Stephens Inc., Richardson, Texas, the contract research organisation (Emmerich, Jiang). Funding by Allergan Aesthetics is stated on the record; the individual author-employer split above is taken from the published affiliation list and was not separately re-verified against an employment record. There is no independent, unfunded author on this paper.
  14. Saunders KE, Reyes JM, Cyril L, Mitchell M, Colter S, Erskine J, McNamara KX, Hunter JC, Perkins KM, Charles A. Notes from the Field: Nontuberculous Mycobacteria Infections After Cosmetic Surgery Procedures in Florida — Nine States, 2022-2023. MMWR Morb Mortal Wkly Rep. 2024 Jan 25;73(3):66-67. PMID 38271297, PMCID PMC10824548.Tier 1Supports: CDC notified the Florida Department of Health on 7 February 2023 of a non-Florida resident with NTM infection after a cosmetic procedure at a south Florida surgery clinic (clinic A). Case definition: isolation of Mycobacterium abscessus from a wound culture in a patient who underwent a cosmetic procedure at clinic A during August-December 2022. Among 19 reported infections, 15 patients from nine US states met the case definition. All 15 were women; median age 33 years (range 24-51). All 15 had liposuction; 12 (80%) had gluteal augmentation with autologous fat transfer; 14 (93%) had more than one procedure. Wound sites: buttocks 10 (67%), abdomen 3 (20%), hip 1, breast 1. Median interval from procedure to symptom onset 69 days (range 33-119). Six (40%) required intravenous antibiotics; four (27%) required additional interventions such as drainage or debridement; one hospitalised; no deaths. Antibiotic courses ran 2-6 months. Whole genome sequencing of seven available isolates found four closely related. Clinic A closed after the cluster was identified, precluding environmental sampling. An on-site assessment at clinic B (same surgeon, staff and protocols) on 3 March 2023 'detected gaps in environmental cleaning practices, use of proper personal protective equipment, and disinfection during surgical device reprocessing.' The specific source was never identified. SCOPE LIMIT: every case followed invasive cosmetic SURGERY performed by a plastic surgeon. No facial device, no hydradermabrasion device and no HydraFacial product is mentioned anywhere in this report. It is cited here solely to establish what the 2022-2023 US aesthetic NTM cluster actually was.
  15. Kim SJ, Baek JH, Koh JS, Bae MI, Lee SJ, Shin MK. The effect of physically applied alpha hydroxyl acids on the skin pore and comedone. Int J Cosmet Sci. 2015 Oct;37(5):519-25. doi 10.1111/ics.12244. PMID 26032934.Tier 3Supports: The only controlled comparison in the indexed hydradermabrasion literature that isolates the physical (negative-pressure) component from the acid. Twenty-three healthy Korean women, mean age 30.17 +/- 5.06 years. Each subject's face was 'randomly divided into test and control groups' — a split-face design. Both sides received the same 4% AHA peeling solution (1000 mL carbonated water, 20 mL glycolic acid, 20 mL lactic acid); the test side additionally received 'chemical peeling combined with negative pressure'. Sebum output (light transmission), pore area and number (optical image analyser) and comedone counts were measured before and at 1, 2 and 4 weeks after a SINGLE treatment. Results, verbatim: 'whiteheads and blackheads were significantly decreased at 1, 2 and 4 weeks in the test group (P < 0.05), but for the control group, whiteheads and blackheads showed a tendency to decrease'; 'at 1 week, whiteheads and blackheads of the test group significantly decreased compared to the control group (P < 0.05)'; pore area and number significantly decreased at 1 week and sebum output at 4 weeks 'only in the test group, which did not show any significant group difference for individual parameters'. Conclusion, verbatim: '4% AHA solution combined with a physical effect had rapidly improving effects on whiteheads and blackheads synergistically.' SCOPE LIMITS: this is NOT a HydraFacial device and the paper does not name any commercial device — it tests the generic mechanism of AHA plus negative pressure; n=23; single treatment; 4-week follow-up; Korean cohort, phototypes not reported; the between-group advantage reached significance only at week 1, and for pore and sebum measures the authors explicitly report no significant between-group difference.Funding / interest: No funding statement is carried on the PubMed record and none was located. Three authors (Kim, Baek, Koh) are at DERMAPRO Ltd. Skin Research Center, Seoul — a commercial contract skin-testing laboratory. The remaining authors are at Kyung Hee University College of Medicine and a private dermatology clinic. A commercial testing-house sponsor cannot be excluded.
  16. 21 CFR 878.4820, Surgical instrument motors and accessories/attachments (US Code of Federal Regulations, Title 21, Part 878, Subpart E).Tier 1Supports: The regulation identifies AC-powered, battery-powered or air-powered surgical instrument motors and lists their accessories/attachments as 'bur, chisel (osteotome), dermabrasion brush, dermatome, drill bit, hammerhead, pin driver, and saw blade' — the 'dermabrasion brush' being the category FDA product code GFE sits in. Classification, verbatim in substance: the device is 'Class I (general controls)' and is 'exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to Sec. 878.9'. This establishes the 510(k)-exempt status from the regulation itself rather than from the manufacturer's characterisation of it. SCOPE LIMIT: the exemption is subject to the limitations in 21 CFR 878.9; exemption from premarket notification is not FDA review, clearance or approval, and says nothing about efficacy.